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Abstract
Background: Pancreatic cancer is one of the direct causes of cancer-related death. High level of chemoresistance is one of
the major obstacles of clinical treatment. In recent years, cancer stem cells have been widely identified and indicated as the
origin of chemoresistance in multi-types of solid tumors. Increasing evidences suggest that cancer stem cells reside in the
cells capable of forming holoclones continuously. However, in pancreatic cancer, holoclone-forming cells have not been
characterized yet. Therefore, the goal of our present study was to indentify the holoclone-forming pancreatic cancer stem
cells and develop an in vitro continuous colony formation system, which will greatly facilitate the study of pancreatic cancer
stem cells.
Methodology/Principal Findings: Pancreatic cancer cell line BxPC3 was submitted to monoclonal cultivation to generate
colonies. Based on the morphologies, colonies were classified and analyzed for their capacities of secondary colony
formation, long-term survival in vitro, tumor formation in vivo, and drug resistance. Flowcytometry and quantitative RT-PCR
were performed to detect the expression level of cancer stem cells associated cell surface markers, regulatory genes and
microRNAs in distinct types of colonies. Three types of colonies with distinct morphologies were identified and termed as
holo-, mero-, and paraclones, in which only holoclones generated descendant colonies of all three types in further passages.
Compared to mero- and paraclones, holoclones possessed higher capacities of long-term survival, tumor initiation, and
chemoresistance. The preferential expression of cancer stem cells related marker (CXCR4), regulatory genes (BMI1, GLI1, and
GLI2) and microRNAs (miR-214, miR-21, miR-221, miR-222 and miR-155) in holoclones were also highlighted.
Conclusions/Significance: Our results indicate that the pancreatic tumor-initiating cells with high level of chemoresistance
were enriched in holoclones derived from BxPC3 cell line. Generation of holoclones can serve as a novel model for studying
cancer stem cells, and attribute to developing new anti-cancer drugs.
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Introduction
Pancreatic cancer is currently the fourth leading cause of
cancer-related mortality. Less than 5% patients survive for 5 years
after diagnosis with the median survival period of 4 to 6 months
[1,2]. Although surgical resection is regarded as the most effective
method of therapy, its feasibility remains low because of local
advancement and early metastasis [3]. In addition, chemotherapy
is considered as an important option in clinical therapy, but it
usually produces poor effects [4,5].Therefore, it is necessary to
decipher the mechanisms underlying the high level chemoresis-
tance of pancreatic cancer cells.
In recent years, cancer stem cells (or termed as tumor initiating
cells) have been identified as an integral part in multi types of solid
tumors [6–11]. Cancer stem cells not only result in tumor
initiation and growth, but also act as the origin of cancer
metastasis, relapse and resistance against chemo- or radiotherapy
[12–14]. Hence, further work on detection and elimination of
pancreatic cancer stem cells is still desired to successfully conquer
the obstacles in clinical therapy.
Recent studies on adult and cancer stem cells have correlated
stem cell properties with the morphology of colonies generated
from single cells [15–20]. According to the criteria of colony size
and borderline defined by pioneering works in keratinocyte cell
lines, the colonies were classified and termed as holoclones,
meroclones, and paraclones [21]. Similar to stem cells in hair
follicles [15], ocular [16], and epidermal [17], cancer stem cells of
prostate [19] and glioma [20] were demonstrated to reside in
holoclones. Holoclones derived from prostate cancer cell line PC3
initiated tumor formation in NOD/SCID mice exclusively and
proliferated in vitro robustly [19]. Cells in holoclones derived from
glioma cell line U251 were able to generate tumor spheres in
serum free condition and differentiate into lineages of neurons,
astrocytes and oligodendrocytes [20]. Interestingly, stem cell
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both prostate cancer and glioma cell lines [19,20]. These clues
suggested that propagation of holoclones from cancer cell lines
could serve as an alternative strategy for enrichment of cancer
stem cells [20]. However, in pancreatic cancer, holoclones have
not been identified and its correlation with properties of cancer
stem cells has not been determined yet.
In the present study, we addressed the heterogeneity in
pancreatic cancer cell lines BxPC3 [22] and PC3 [23] based on
the morphology of colonies derived from single cancer cells and
demonstrated that cancer stem cell properties were enriched in
holoclones exclusively. Furthermore, our work indicated the
holoclone forming cells attribute to chemoresistance, which
indicated its potential value to develop chemotherapeutic drugs.
Results
Pancreatic cancer cells exhibit heterogeneous capacity to
generate diverse colony morphologies in clonal culture
The first aim of our study was to determine whether the diversity
ofclonal morphologiesexistsinpancreaticcancercellpopulation,so
monoclonal cultivation was carried out (Fig. 1A) with pancreatic
cancer cell line BxPC3. This cell line was derived from primary loci
of pancreatic adenocarcinoma and with typical epithelium
morphology. After plated, a portion of cells died, while the others
werekept viable and formed colonies within 3 days after plating and
showed a spectrum of distinguishable morphologies after 5–7 days.
Based on differences in morphology, colonies were defined as
holoclones, meroclones and paraclones (Fig. 1B, C, D) [21].
Holoclones were clusters of homogeneous, small and tightly packed
cells with regular and smooth colony borderlines (Fig. 1B).
Paraclones consisted of dispersed and larger cells with fragmented
borderlines (Fig. 1D). Meroclones exhibited intermediate morphol-
ogies (Fig. 1C). These mophologies were maintained when size of
colonies increased. With parallel assays performed with PC3 cell
line, three types of colonies were identified (Fig. S1A, B, C) with the
morphologies similar to those derived from BxPC3 cell line. The
colony composition was similar in these two cell lines: nearly half of
the colonies were meroclones, whereas holoclones and paraclones
accounted for about 20–30% of the colonies formed (Fig. 1E, Fig.
S1D). Therefore, these data indicated the diversity of clonal
morphologies in pancreatic cancer cell population.
Different types of colonies possess differential capacities
for self-renewal and long-term proliferation
Sincetheclonalmorphologicaldiversityinpancreaticcancercells
hadbeenindicated, the secondary colony formationcapacityshould
be assessed. For this purpose, cells from all three types of colonies
were isolated and replated with low density (less than 200 cells per
well of 6-well plate) for several passages. At initial passage, the
holoclones generated similar proportions of secondary holoclones
and meroclones (nearly 50% each), with limited number (less than
10%) of paraclones (Fig. 2A, Fig. S2A). In parallel assays, cells
isolated from meroclones produced a rare number of secondary
holoclones but a much higher percentage of paraclones (Fig. 2C,
Fig. S2C). However, rare cells of paraclones were kept viable after
re-plating and generated only secondary paraclones at low
frequency (data not shown). To follow the developmental fate of
colonies, typical colonies of distinct type were selected for long-term
culture. Cells in selected colonies were passaged routinely at clonal
density under common condition.Forcolonies derived from BxPC3
cell line, all 12 holoclones were viable and proliferated robustly,
whereas 12 of 18 meroclones and 13 of 15 paraclones were
gradually aborted (Fig. 3) during parallel culture of 140 days.
Similarly, during 60 days’ passage of colonies derived from PC3 cell
line, 8 of 9 holoclones were in robust expansion while 4 of 8
meroclones and 6 of 8 paraclones declined in short period (Fig. S3).
Figure 1. Colony heterogeneity in pancreatic cancer cell line
BxPC3. (A) Schematic depicting the procedure of deriving BxPC3 cell
clonal cultures and functional assays. Lower panels show representative
holoclones (B), meroclones (C) and paraclones (D) from BxPC3 cultures.
All photographs were taken at 2 weeks after plating (Bar, 100 microns).
At this time point, each type of colonies was counted (E). The results
from repeated experiments (n=4) are presented as means6 s.e.m in
histogram.
doi:10.1371/journal.pone.0023383.g001
Figure 2. Self-renewal capacity of distinct types of colonies.
Cells isolated from single colonies were plated at low density under
common condition. (A) At the initial passage, holoclones (n=8) mainly
produced similar frequencies of descendant holoclones and mero-
clones, whereas much lower percentages of paraclones were generat-
ed. (B)After passages of one more month, holoclones (n=8) generated
the full range of progeny colonies at frequencies similar to those
retained in unsorted parental cell lines. (C) Meroclones (n=8) mainly
produced paraclones and meroclones, and few holoclones were
generated.
doi:10.1371/journal.pone.0023383.g002
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range of colonel morphologic phenotypes and restored the
proportions of each type of colonies (Fig. 2B, Fig. S2B) similar to
the proportions observed in unsorted parental cell lines under low
density culture. Based on the distinct appearance exhibited above,
the capacity of long-term self-renewal in vitro mainly resided in
holoclones, but not meroclones or paraclones.
Holoclones, but not meroclones or paraclones, initiate
tumor formation and support tumor serial
transplantation in NOD/SCID mice
For the robustness of holoclones had been shown in vitro,i tw a s
important to evaluate the in vivo tumorgenecity of three types of
colonies. In order to estimate the tumor formation capacity of each
type of colony, serial transplantation assays were performed. Firstly,
unsorted BxPC3 cells initiated tumor formation in a dose dependent
manner. 100% of mice injected with 10
6 or 10
5 BxPC3 cells
developed xenograft tumors after 14 days, and mice injected with 10
4
or 10
3 cells also developed xenograft tumors after 21 days with 100%
efficiency (Table 1). After that, three holoclones, three meroclones,
andtwoparacloneswerepickedoutfortransplantation.10
4holoclone
cells formed palpable tumors in 100% of mice (15 of 15 mice) within
18 days. On the contrary, no visible tumors were formed by cells from
m e r o -o rp a r a c l o n e s( 0o f3 6m i c e ,1 0
4,10
5 cells per mouse) within 2
months (Table 1). In a further step, cells in xenograft tumors derived
from holoclones were then purified and re-transplanted to NOD/
SCID mice (10
4 cells per mouse). Within 18 days, all recipient mice
(18 of 18 mice) developed palpable tumors (Table 1). Serial
transplantation assays were also performed on PC3 cell line. Unsorted
parental cell line, 3 holoclones, 2 meroclones, and 2 paraclones were
employed. All the holoclones derived from PC3 cell line were able to
develop tumor exclusively in short latency (Table S3).
Exnograft tumors derived from unsorted BxPC3 cell line and
corresponding holoclones were analyzed with H&E staining. The
histological characteristics of xenograft tumor speciments was
visualized and showed high level of similarity between tumor
samples from unsorted cell line (Fig. S4A, B) and corresponding
holoclones (Fig. S4C, D).
With the significant difference of tumor formation capacity
among distict types of colonies, it was suggested that the tumor-
initiation capacity in vivo was enriched in holoclones rather than
meroclones or paraclones.
Cancer stem cells related surface markers, genes and
microRNAs are differentially expressed in distinct types of
colonies
Based on the characteristics of holoclones in vitro and in vivo,i t
was necessary to analysis the expression of cell-surface markers
Figure 3. Long-term propagation capacity of distinct types of
colonies. Holoclones (n=12, red line), meroclones (n=18, green line)
and paraclones (n=15, blue line) were cultured in common condition
for 20 weeks and life spans of each colony were recorded. Most of the
meroclones and paraclones were aborted gradually, whereas all the
holoclones remained viable (p,0.01).
doi:10.1371/journal.pone.0023383.g003
Table 1. Tumorgenecity of distinct types of colonies.
Types of colonies Clone Cell number Tumor incidence
Mean weight of tumor
(g)
Termination/latency
(day)
Unsorted 10
6 100% (3/3) 30/14
10
5 100% (3/3) 30/14
10
4 100% (3/3) 30/21
10
3 100% (3/3) 30/21
Para E03 10
4 0% (0/6) 60
E03 10
5 0% (0/6) 60
mero E04 10
4 0% (0/6) 60
E04 10
5 0% (0/6) 60
C02 10
4 0% (0/6) 60
C02 10
5 0% (0/6) 60
Holo C07 1u 10
5 100% (5/5) 2.33 48/17
C07 2u 10
4 100% (6/6) 0.4 30/15
D11 1u 10
5 100% (5/5) 2.49 48/16
D11 2u 10
4 100% (6/6) 0.5 30/17
D10 1u 10
5 100% (5/5) 3.93 48/14
D10 2u 10
4 100% (6/6) 0.69 30/16
NOTE: Cells from BxPC3 clones (1u) at the indicated numbers were injected subcutaneously with 1:1 mixture of RPMI-1640 and Matrigel into the dorsolateral part of
NOD/SCID mice. Secondary (2u) transplantation experiments were carried out as described in ‘‘Materials and Methods’’.
doi:10.1371/journal.pone.0023383.t001
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colonies. Therefore, flow-cytometry and quantitative RT-PCR
were employed simultaneously. Flow-cytometric assays showed
that CD133 was negative (Fig. 4A) and CD44 was positive (Fig. 4C)
in holoclones, meroclones and paraclones. All types of colonies
contained both CXCR4
+ and CXCR4
2 cells, however, the
percents of CXCR4
+ cells were much higher in holoclones than in
meroclones and paraclones (Fig. 4B). The CD24 intensity (Fig. 4D,
Fig. S5) was significantly stronger in paraclones than in holoclones.
Similar results were obtained with quantitative RT-PCR. CD133
was not detectable and CD44 showed less than 1.3-fold of up-
regulation in holoclones than in paraclones (Fig. 4E). However,
expression of CD24 in holoclones was down-regulated for above 5-
fold than in paraclones (Fig. 4F). Expression level of CXCR4 was
about 3-fold higher in holoclones than in paraclones (Fig. 4G).
Furthermore, Expression of BMI-1, GLI1, GLI2, GLI3 and a list of
cancer related microRNAs were also quantified. BMI-1, GLI1 and
GLI2 were up-regulated in holoclones rather than in paraclones,
while expression level of GLI3 was not significantly changed
among three types of colonies (Fig. 5A). MicroRNAs were showed
differentially expressed and clustered into two groups: one group
was up-regulated in holoclones, including miR-214, miR-21, miR-
221, miR-222, and miR-155 (Fig. 5B); the other group was down-
regulated in holoclones, including Let-7a and miR-30c, miR-30b,
miR-30a (Fig. 5C). The differential expression of markers and
regulators also suggest the tendency that stem cell properties were
possessed by holoclones rather than other two types of colonies.
Holoclones exhibit much higher chemoresistance than
meroclones and paraclones
It’s well known that chemoresistance is one of the major
properties of cancer stem cells, so here we asked whether the
holocoloes possess this ability. Hence, the cells isolated from these
three types of colonies and treated with gemcitabine and 5-FU
under increasing concentration. Among the entire concentration
range tested, the survival rates of cells derived from holoclones
were significantly higher than those from meroclones and
paraclones (Fig. 6A, B). The IC50 value of 5-FU was
2.59610
3 nM in holoclones, which was much higher than those
of meroclones (1.24610
2 nM) and paraclones (15.10 nM). To
analyze the gene expression change induced by drug treatment,
quantitative RT-PCR was carried out with the cell treated with
drugs. After treatment with 50 nM of 5-FU for 12 hours,
expression of the drug-intake transporters (SLC28A1, SLC28A2,
SLC28A3, SLC29A1, SLC29A2, SLC29A3) were all up-regulated in
paraclones with no effect in holoclones mostly (only SLC28A1 was
down-regulated about 2-fold) (Fig. 6C).With the parallel treatment
of gemcitabine, similar responses of these genes were detected
(Fig. 6C). Taken together, SLC28A1/A2 and SLC29A1/A3 were
commonly up-regulated more dramatically in paraclones than in
holoclones after treatments of gemcitabine or 5-FU. This
differential response might be, at least partly, invovled in the
variation of chemoresistance among three types of colonies.
Discussion
In present study, we demonstrated the stem cell properties of
holoclones and indicated that a panel of stem cell associated genes
and microRNAs were preferentially expressed in holoclones.
Moreover, we revealed a high level chemoresistance in holoclones
and suggested the potential value of holoclones in study of cancer
stem cells.
We are the first to show the heterogeneity in clonoal
morphologies of pancreatic cancer cells. Similar to the behavior
of keratinocyte [21] and multiple cancer cell lines [18–20], when
cells of BxPC3 and PC3 cell line were plated monoclonally, a serial
of colonies with diverse morphologies were developed (Fig. 1A).
Based on the morphological diversity, holoclones (Fig. 1B, Fig.
S1A), meroclones (Fig. 1C, Fig. S1B) and parclones (Fig. 1D, Fig.
S1C) can be easily identified.
Furthermore, our results indicated that stem-like cancer cells
were enriched in holoclones rather than mero- or paraclones.
During in vitro propagation, cells in holoclones generated a high
percentage of progeny holoclones at the first round of passage
(Fig. 2A, Fig. S2A). After more passages, cells in holoclones
generated colonies with full-range of morphological characteristics
similar to that derived from unsorted parental cell lines (Fig. 2B,
Fig. S2B). However, meroclones generate a limited level of
holoclones and much higher percentages of paraclones (Fig. 2C,
Fig. S2C). During long-term of passages in vitro, holoclones showed
more robustness and constant proliferation, while mero- and
paraclones declined rapidly (Fig. 3, Fig. S3). With the differences
shown above, distinct types of colonies possessed differential
capacity of self-renewal and proliferation capacity. More impor-
tantly, holoclones serially initiated tumor development in vivo while
mero- and paraclones did not (Table 1, Table S3), which is
regarded as the widely used golden standard for identification of
cancer stem cells. As an indispensable supplement, the xenograft
tumors derived from BxPC3 holoclones showed similar histolog-
ical characteristics with those tumor tissue derived from unsorted
BxPC3 cell line (Fig. S4). In prostate cancer cell lines PC3 [19] and
DU145 [24], similar characteristics of holoclones in vitro and in vivo
had been indicated and served as evidences to support the stem
cell property of holoclones.
Moreover, expression of cell surface markers, genes and
microRNAs among distinct types of colonies also suggested the
stem cell property of holoclones. Firstly, the cell surface markers of
pancreatic cancer stem cells, CD44, CD24, and CD133, were
evaluated. Based on two independent reports, pancreatic cancer
stem cells were identified as population of CD44
+CD24
+ESA
+ or
CD133
+, however, these two populations showed little overlap
with each other [10,11]. According to the results of flowcytometry
(Fig. 4A, C) and quantitative RT-PCR (Fig. 4E) assays, expression
of CD133 (undetectable) and CD44(highly expressed) were both
undistinguishable among three types of colonies. The expression of
CD24 was downregulated in holoclones than in paraclones (Fig. 4F,
Fig. S5), which is potentially varied from former report [10].
Similar to the unexpected expression status of CD133 [11,25] and
CD24 [10] in pancreatic cell lines BxPC3 and PC3, divergent
expression of CD133 in one certain cell line was also reported in
ovarian cancer cell lines OVCAR3 and SKOV3 [26–28], which
might at least partly due to some undetermined changes induced
during long-term cultivation in vitro. Moreover, CD133- cancer
stem cells have been identified in glioma and suggested as more
primordial driven force of tumor development than CD133+ cell
population [29]. For further assessment of the stem cell properties
of holoclones, a series of genes and mciroRNAs associated with
cancer stem cells were quantified. Among the genes up-regulated
in holoclones, BMI1 (Fig. 5A) has been shown to play key
regulatory role in self-renewal of neural [30], mammary [31],
hematopoietic [32] stem cells and multi types of cancer stem cells
[31,33,34]. What’s more, BMI1 promoter has been utilized to
drive EGFP as an intracellular marker to enrich hematopoietic
stem cells [35]. Similar to our results, BMI1 had been recently
reported preferentially expressed in holoclones derived from
glioma cell line [20]. The elevation of GLI1 and GLI2 in
holoclones (Fig. 5A) suggests higher activity of Hedgehog
signaling, which was consistent with the higher level of SHH
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+CD24
+ESA
+ cancer stem cells isolated from
human primary pancreatic cancer specimens [20]. The Hedgehog
signal pathway also plays an essential role in maintaining cancer
stem cells in mammary [31] and brain [36]. CXCR4, the pivotal
mediator of metastasis, was up-regulated in holoclones (Fig. 4B, G)
too. In CD133
+ pancreatic cancer stem cells, the CXCR4
+
subpopulation is more invasive than autologous CXCR4
2
subpopulation [11]. Among microRNAs up-regulated in holo-
clones, miR-214, miR-221, miR-222 and miR-155 (Fig. 5B) were
commonly overexpressed in breast cancer stem cells [37].
However, Let-7a (Fig. 5C), which was significantly down-regulated
in holoclones, plays a negative role in self-revewal, tumorigenicity,
and chemoresistance of breast cancer stem cells [12]. Similarly,
miR-30a/b/c (Fig. 5C) were also overexpressed in paraclones. In
breast cancer, this microRNA family inhibits self-renew of stem
cells, induces apoptosis, and reduces the metastasis to lung [38].
Higher level of chemoresistance was indicated in holoclones
rather than in meroclones and paraclones (Fig. 6A, B), which is
consistent with the supportive role of cancer stem cells in
chemoresistance reported previously [11,13]. In accordance with
the robust chemoresistance in holoclones, genes and microRNAs
that sustain chemoresistance, including BMI1 [39], GLI1/2 [40],
CXCR4 [41], miR-214 [42], miR-21 [43], and mir-155 [44] (Fig. 4G,
Fig. 5A, B) were up-regulated in holoclones. In response to drug
treatments, the expression of drug-intake transporters, of which
the higher expression level was correlated with longer survival of
patients [45–48], was induced in paraclones preferentially
(Fig. 6C). This means the drug in-take will be increased more
rapidly in paraclones than in holoclones. This could be one of the
potential origins of preferential survival of cancer stem cells versus
non-stem cancer cells in chemotherapy.
Taken together, the colonies with distinct morphologies and in
different stages of differentiation can serve as a potential model for
analysis of cancer stem cells (Fig. 7). With this model, genes and
microRNAs potentially correlated with cancer stem cells can be
identified. More importantly, parallel evaluation of chemotheraputic
drugs can be carried out on cancer stem cells and autologous non-
stem cancer cells. This means the clonal morphologies based cancer
stem cell model will be useful to lead to the newer understanding of
chemoresistance, which should be quite different from those obtained
from heterogeneous cancer cell populations, and will be helpful to
overcome the chemoresistance in cancer therapy.
Materials and Methods
Cell lines
Human pancreatic adenocarcinoma cell line BxPC3 (purchased
from Cell Bank of China Academy of Sciences, Shanghai, China)
and PC3 were (purchased from China Union Medical Collage,
Beijing, China) cultured in RPMI-1640 (Hyclone) with 10% heat
inactivated fetal bovine serum (Hyclone) and passaged as 1:10 with
0.25% trypsin/EDTA (Hyclone) . These cell line were established
from primary pancreatic ductal adenocarcinoma and with typical
epithelium morphology [22,23]. BxPC3 [22] was derived from
European descent and PC3 [23] was derived from Chinese.
Chemical drugs
Lyophilized powder of gemcitabine (Lilly) was dissolved in
Calsium/Magnesium free PBS (Hyclone) and stored at 220uC
with concentration of 4 mg/ml. 5-FU solution (Roche) was stored
at 220uC with concentration of 25 mg/ml. Before use, stocks
were diluted to working concentrations (5, 10, 50, 100, and
500 nM for 5-FU, and 1, 5, 10, 50, and 100 nM for Gemcitabine)
with culture medium.
Animals
All experiments were approved by the Animal Care and Use
Committee of Peking University (approval number was
IRB00001052-09051). NOD/SCID mice were purchased from
Experimental Animal Sciences Center of Peking University and
maintained in standard condition according to the institutional
guidelines.
Single cell cloning
Cells were harvested at 70%,80% of confluence with Accumax
(Chemicon) and resuspended in medium without serum. Single
Figure 5. Differential expression of regulatory genes and microRNAs associated with cancer stem cells. BMI1, GLI1, and GLI2 were up-
regulated in holoclones, while expression of GLI3 showed no significant change among distinct types of colonies (A). The microRNAs were clustered
into two groups, which were elevated (B) and repressed (C) in holoclones respectively. All expression values in distinct types of colonies were
normalized against those in paraclones (*, p,0.05).
doi:10.1371/journal.pone.0023383.g005
Figure 4. Expression of cancer stem cell markers in holoclones, meroclones and paraclones. Cells isolated from holoclones, meroclones
and paraclones were examined with flowcytometry for the cell surface markers of cancer stem cells. CD133 (A) was totally negative in all three types
of colonies. The CXCR4
+ cells (B) were detectable in all types of colonies but significantly enriched in holoclones. CD44 (C) was strongly positive and
with little difference among distinct types of colonies, while CD24 (D) was expressed at a higher level in paraclones than in holoclones. mRNA level of
CD44 (E), CD24 (F) and CXCR4(G) in holo-, mero-, and paraclones was also quantified with real-time PCR (GAPDH as the internal reference) and similar
trends were showed (*, p,0.05).
doi:10.1371/journal.pone.0023383.g004
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cytometry (DakoCytomation). Two days after plating, 96-well
plates were checked with microscopy. Wells containing only one
viable cell were marked. And then, medium was refreshed every 3
days. Colonies were classified as holo-, mero-, and paraclones
according to their morphologies. 14 days after flow-cytometric
sorting, typical colonies were selected for further experiments.
Tumor cell implantation
Selected colonies were expanded and harvested with Accumax
(Chemicon), counted and resuspended in 1:1 mixture of RPMI-
1640 and Matrigel (BD). Aliquots of cell suspension were injected
subcutaneously into dorsolateral part of NOD/SCID mice.
Tumor latency (i.e., time from injection to detection of palpable
tumors) was determined. Within 9 weeks after implantation,
tumor-bearing mice were sacrificed. Meanwhile, xenograft tumors
were dissected out surgically and weighed. Mice with no sign of
tumor burden were kept for at least 9 weeks since implantation
and then examined on necroscopy to confirm that they were
tumor-free.
For serial transplantation, xenograft tumors were minced into
small pieces with scissors, suspended in M199 medium, and
digested at 37uC for about 3 hours with 200units/ml ulturapure
collagenas IV (Worthington Biochemicals). Further mechanical
digestion was performed with a 25-ml pipette every 15 minutes.
After digestion, cell suspension was filtered through a 40-mm nylon
mesh and gently loaded onto the top layer of Histopaque-1077
gradient (Sigma-Aldrich) (1,3610
6 cells/ml histopaque used in
total volume of 3 mL) and then centrifuged at 4006g for
30 minutes at room temperature. Viable nucleated cells were
collected at the interface, while red blood cells, dead cells and
debris were eliminated. The harvested single-cell suspension was
used for transplantation as described above.
Chemoresistant assay
Cells from the same type of colonies were harvested, pooled
together and seeded into 96-well plates with density of 5000 cells/
well. 24 hours later, medium was refreshed and drugs (gemcita-
bine or 5-FU) were added. After 72 hours of drug treatment, 10%
volume of WST-8 reagent (Beyotime) was added into all wells and
plates were incubated at 37uC for 1 hour. The absorbance at
450 nm wavelength was measured with plate-reader (Bio-Rad).
Based on the survival rate under different drug concentration,
IC50 were calculated.
Flowcytometric assay
Cells harvested from pooled colonies of the same type were
resuspended in HBSS containing 2% FBS at concentration of 10
6
cells/ml. Antibodies were then added into the sample aliquots.
After 30 minutes incubation on ice, the samples were washed
Figure 6. Differences in chemoresistance among holoclones, meroclones and paraclones. Cells isolated from holoclones, meroclones and
paraclones were treated with chemotherapeutic drugs of increasing concentration: 1, 5, 10, 50, 100 nM of gemcitabine (A) or 5, 10, 50, 100, 500 nM of
5-FU (B). For each concentration value, three wells were set as repeat in a single experiment and three times of representative experiments were
performed. The expression changes of chemo-drug intake transporters were quantified in holoclones and paraclones respectively after treated with
50 nM chemo-drug for 12 hours. (C) (*, p,0.05).
doi:10.1371/journal.pone.0023383.g006
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(BD). Following antibodies were used: PE-Cy5 conjugated anti-
human/mouse CD44 (eBioscience), PE conjugated anti-human
CD24 (eBioscience), PE conjugated anti-human CD133 (milte-
nyibiotec) and APC conjugated anti-human CXCR4 (eBioscien-
ce). Pulse width and side scatter profiles were used to eliminate cell
doublets, dead cells and cell debris.
Quantitative RT-PCR
Total RNA (including microRNA) was extracted from the cells
with miRNeasy Kit (Qiagen) according to the user manual.
Reverse transcription reactions for both mRNAs and microRNAs
were carried out with miScript Reverse Tanscription Kit (Qiagen).
Quantitative PCR assays for mRNAs were performed with
SYBR Green PCR Master Mix (QPK-201) (TOYOBO). The
PCR reactions were performed with following condition: 2 min at
95uC, followed by 35 rounds of 15 sec at 95uC and 1 min at 60uC.
The relative expression of each gene was normalized against
GAPDH. Primers used were shown in Table S1.
Quantitative PCR assays for microRNAs were performed with
the miScript SYBRH Green PCR Kit (Qiagen). The PCR reactions
were performed with following condition: 15 min at 95uC, followed
by 35 rounds of 15 sec at 95uC and 30 sec at 55uC and 30 sec at
72uC. The relative expression of each microRNA was normalized
against RNU-6b. Primers were all purchased from Qiagen. Their
codes and catalog numbers were shown in Table S2.
All assays were performed with ABI PRISM 7300 Sequence
Detection System and under the control of ABI 7300 SDS
Software version 1.3.1.
H&E staining
Tissue samples were dissected from mice and fixed in 10%
phosphate buffered formalin. After fixed, tissues were embedded in
paraffin. According to standard histopathologic procedures,
sections were cut 4-Am thick, mounted on poly-L-lysine coated
slides, dried overnight at 37uC, dewaxed in xylene, rehydrated and
stained with H&E.
Supporting Information
Figure S1 Colony heterogeneity in pancreatic cancer
cell line PC3. Panels show representative holoclones (A),
meroclones (B) and paraclones (C) from PC3 cultures. All
photographs were taken at 2 weeks after plating (Bar, 100 mi-
crons). At this time point, each type of colonies was counted (D).
The results from repeated experiments (n=4) are presented as
means6 s.e.m in histogram.
(TIF)
Figure S2 Self-renewal capacity of distinct types of
colonies derived from PC3 cell line. Cells isolated from
single colonies were plated at low density under common
condition. (A) At the initial passage, holoclones (n=9) mainly
produced similar frequencies of descendant holoclones and
meroclones, whereas much lower percentages of paraclones were
generated. (B)After passages of one month, holoclones (n=8)
generated the full range of progeny colonies with the frequencies
similar to those retained in unsorted parental PC3 cell line. (C)
Meroclones (n=8) mainly produced similar amount of paraclones
Figure 7. The model of hierarchical organization of pancreatic cancer cell population. The pancreatic cancer stem cells and their
progenies in differentiation can develop to single colonies with different morphologies. Based on the in vivo and in vitro characteristics, Holoclones
correspond to the cancer stem/progenitor cells, while paraclones correspond to the fully differentiated cells and meroclones correspond to the cells
in the intermediate stage. The genes and microRNAs that associate with cancer stem cells and support chemoresistance, including BMI1, GLI1/2,
CXCR4, mir-21/214/221/222/155, are enriched in holoclones. However, the Let-7 and mir-30a/b/c are enriched in paraclones.
doi:10.1371/journal.pone.0023383.g007
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neously.
(TIF)
Figure S3 Long-term propagation capacity of distinct
types of colonies derived from PC3 cell line. Holoclones
(n=9, red line), meroclones (n=8, green line) and paraclones
(n=8, blue line) were passage under common condition for 2
months. Life spans of each colony were recorded. 4 of 8
meroclones and 6 of 8 paraclones were aborted gradually, whereas
8 of 9 holoclones remained viable (p,0.01).
(TIF)
Figure S4 Histological characteristics of exnograft
tumors derived from unsorted BxPC3 cell line and
holoclones. 10
4 cells from unsorted cell line and holoclones
were employed to produce xenograft tumors. H&E staining was
performed to analyze the histological features of xenograft tumors
derived from unsorted BxPC3 cell line (A) and holoclones (C) (Bar,
400 microns). The selected areas (black box) in panel A and C
were magnified as panel B and D respectively (Bar, 100 microns).
(TIF)
Figure S5 Expression of cancer stem cell markers CD44
and CD24 in holoclones and paraclones derived from
pancreatic cancer cell line PC3. Cells in holoclones and
paraclones derived from PC3 cell line were examined with
flowcytometry for the cell surface markers of cancer stem cells.
Flowcytometric plots (A) showed that CD44 (trunnion axis) was
strongly positive and with little difference among distinct types of
colonies. Three gates were set up to show the high (R1), medium
(R2) and low (R3) level of CD24 (vertical axis) expression.
Representative plots showed that cells isolated from paraclones
(right panel) tended to be distributed in gate R1 while cells isolated
from holoclones (left panel) were dominantly distributed in gate
R3. The distribution of cells in three gates was summarized (B) as
below (p,0.05).
(TIF)
Table S1 Primers for real-time PCR of genes.
(DOC)
Table S2 Primers for real-time PCR of microRNAs.
(DOC)
Table S3 Tumorgenecity of distinct types of colonies derived
from PC3 cell line.
(DOC)
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